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Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival (relative risk 1.9, 95% CI:
1.2–3.0), particularly among women who received adjuvant chemotherapy (10-year survival 27 vs 69%, P¼0.0003), and was
significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment
decisions.
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Angiogenesis is under intense study both for its prognostic value
and for the potential therapeutic value of interfering with
angiogenic pathways. In breast cancer, both higher vascular
endothelial growth factor (VEGF) levels (Blackwood and Weber,
1998; Linderholm et al, 2000) and increased microvessel density
(MVD) (Weidner et al, 1991, 1992; de Jong et al, 2000) are
associated with a poorer prognosis. Recent microarray studies
have also identified an association between the expression of genes
involved in angiogenesis, such as VEGF, and poor prognosis
following breast cancer (van’t Veer et al, 2002). Furthermore, the
proangiogenic genes COL4A1 and ECGF1 are overexpressed in
breast cancers found in BRCA1 mutation carriers, although their
prognostic value in such women is unknown (van’t Veer et al,
2002). Here, we describe our results with a morphological marker
of prognosis of potential importance in the management of women
who carry germline BRCA1 mutations. Glomeruloid microvascular
proliferations (GMPs) (Figure 1) are focal proliferative buddings of
vascular endothelial cells resembling a renal glomerulus. Glomer-
ular microvascular proliferation has been predominantly asso-
ciated with glioblastoma multiforme (Wesseling et al, 1998), the
most aggressive form of glioma. They can be produced in athymic
mice by overexpressing VEGF using an adenovirus vector
(Sundberg et al, 2001). Recent evidence suggests that these
structures may be present and prognostically useful in other
tumour types, including breast cancer (Straume et al, 2002). The
work presented here is an expansion of the breast cancer data
presented by Straume et al, and focuses on two new aspects: (1) the
inter-relationship between GMP, p53 overexpression and BRCA1/2
status and (2) the effect of GMP on prognosis in the presence or
absence of adjuvant chemotherapy.
MATERIALS AND METHODS
A total of 292 consecutive Ashkenazi Jewish women aged 65 years
or less with primary nonmetastatic breast cancer diagnosed at one
Montreal institution between 1980 and 1995 were assessed.
Sufficient follow-up and tissue were available for 251 subjects.
Following ethics committee approval, specimens were evaluated by
one pathologist (LR Be ´gin) using conventional methods. Accumu-
lation of p53 protein was detected by immunohistochemistry as
previously described (Yuan et al, 1999). Pathology blocks from all
women were tested for founder BRCA1 mutations (185delAG,
n¼18; 5382insC, n¼10) and BRCA2 mutation (6174delT, n¼8)
that are common in this population, using established techniques
(Foulkes et al, 1997).
Staining of endothelial cells by Factor-VIII (A-0082, Dako,
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yembedded archival material as previously published (Straume and
Akslen, 2001). The presence of GMP was recorded by the finding of
focal glomerulus-like aggregates of closely associated and multi-
layered factor-VIII positive endothelial cells. Glomerular micro-
vascular proliferations consisted of 15–100 cells. Lumen formation
was not necessary for the aggregates to be counted as GMPs.
Tangentially sectioned normal vessels, or nonspecific Factor-VIII
positivity in stromal components, were excluded. Glomerular
microvascular proliferations were categorised as being absent
(group 0), rare (not more than one per high-power field (HPF),
group 1), or greater than 1 per HPF (group 2). Microvascular
density was calculated as the mean number of stained vessels in 10
high-power fields ( 400).
Molecular, pathological and clinical assessments were collected
in a mutually blinded manner in a retrospective cohort approach.
Subject characteristics were compared using Wilcoxon, t-test, and
Fisher’s exact testing, with trends in increasing odds ratios being
assessed by Cochran–Armitage’s test. Differences in breast cancer-
specific survival were calculated using the method of Kaplan and
Meier. The Cox proportional hazards model was used to assess
prognostic factors.
RESULTS
In all, 43 breast cancers (17%) had one or more GMP, with 36
tumours in group 1 and seven in group 2. Their presence was
associated with higher nuclear grade (P for trend o0.0001),
oestrogen receptor (ER) negativity (OR 4.7, 95% CI: 2.3–9.6), p53
immunohistochemical positivity (OR 4.1, 95% CI: 2.0–8.2), and
germline BRCA1 mutations (odds ratio (OR) 2.6, 95% CI: 1.1–6.3),
but not tumour size, axillary nodal status, microvascular density
(MVD) or germline BRCA2 mutations (Table 1). There was no
relationship between higher GMP grouping and higher MVD or
BRCA1 mutation type.
There were 65 breast cancer deaths in this series of women at 10
years follow-up. Kaplan–Meier survival analysis showed that
50.3% of women with GMP died of breast cancer over this period,
whereas the mortality was 25.7% for those with no identified GMP
(P¼0.0003). Microvascular density was not significantly asso-
ciated with a worse prognosis (P¼0.47). In a Cox proportional
hazards model, the presence of GMP (defined continuously) was
associated with a poor prognosis (relative risk (RR) 1.9, 95% CI:
1.2–3.0) as was positive lymph node status (RR 2.3). Nuclear grade
(RR 1.6) and negative ER status (RR 1.7) were of borderline
significance, while tumour size, p53 positivity and carrier status
did not achieve significance (Table 2). Among women treated with
adjuvant chemotherapy, the presence of GMP was an indicator of
poor prognosis (10-year survival 27 vs 69%, P¼0.0003), while
among women not treated with chemotherapy, no statistically
significant difference in survival was seen on the basis of GMP
status (10-year survival 75 vs 79%, P¼0.4).
DISCUSSION
This study is the first to demonstrate that GMP is associated with
p53 expression and the presence of germline BRCA1 mutations
and it suggests that the presence of GMP is an independent risk
factor for death from breast cancer comparable in magnitude to
conventional prognostic factors (RR 1.9).
Notably, GMP was not associated with a higher MVD, and the
latter was not prognostic for poor survival in our cohort of
patients. Vascular endothelial growth factor is implicated in the
Figure 1 A GMP from a BRCA1:5382insC-related breast cancer is
shown.














1 2 (4) 61 (30)
2 15 (35) 84 (41) o0.0001
b
3 26 (60) 61 (30)
Oestrogen receptor (247)
Positive 14 (33) 144 (70)
Negative 28 (67) 61 (30) o0.0001
Lymph node status (228)
Positive 17 (44) 90 (48) 0.73
Negative 22 (56) 99 (52)
Microvascular density (251)
Median (range) 112.5 (43.8-306.3) 115.6 (37.5-393.8) 0.27
BRCA-carrier status
BRCA1 carrier 9 (21) 19 (9) 0.04
BRCA2 carrier 1 (2) 7 (3) 0.99
Non-carrier 33 (77) 182 (88)
p53 IHC (245)
Positive 21 (50) 40 (20)
Negative 21 (50) 163 (80) 0.0001
GMP¼glomeruloid vascular proliferation; IHC¼immunohistochemistry.
aNumber in parenthesis indicates cases with available data.
bFor trend.
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ygenesis of both GMP (Sundberg et al, 2001) and increased MVD
(De Paola et al, 2002), but the lack of association between GMP and
MVD suggests that their developmental pathways may differ. In
our cohort, p53 expression was associated with the presence of
GMP, but not with increased MVD (P¼0.8), the latter being
consistent with the literature (Tas et al, 2000). Functional p53
impedes angiogenesis through the regulation of VEGF transcrip-
tional factors Sp1 (Mandlekar and Kong, 2001) and the HIF-1a
subunit (Ravi et al, 2000), as well as by upregulating thrombos-
pondin-1 expression (Dameron et al, 1994). Mutated p53 may be
one pathway by which a neovascular phenotype associated with
GMP (but not MVD) formation is promoted.
Our data suggest that GMP is associated with p53 expression
and BRCA1 germline mutations and that all three of these factors
may be associated with a worse survival (for details of the p53-
BRCA1 relationship, see Goffin et al, 2003). Interestingly, patients
who were treated with adjuvant chemotherapy had a poorer
outcome if their tumours demonstrated GMP. Glomerular micro-
vascular proliferation was highly significantly associated with p53
expression (P¼0.0001), a protein partly responsible for inducing
apoptosis in chemotherapy-treated cells and thus potentially
responsible for diminished responsiveness to chemotherapy
(Fisher, 2001). Opposed to this is the association of GMP with
BRCA1 mutations and higher nuclear grade, both of which appear
to increase tumour responsiveness to chemotherapy (Chappuis
et al, 2002;Wang et al, 2002). In the present study, higher nuclear
grade (RR 1.9, P¼0.02) and age o 50 years (RR 5.6, P¼0.0001)
were associated with an increased likelihood of a woman receiving
adjuvant chemotherapy, while other factors were not significant on
multivariate analysis. The apparent contradiction in associations
and chemoresponsiveness is likely a product of the interplay of
several response mitigating pathways and the incomplete associa-
tion between measured factors.
There is evidence that BRCA1-related breast cancers have a
distinct profile on microarray analysis (van’t Veer et al, 2002) and
that these cancers have a distinctive spectrum of TP53 mutations
(Greenblatt et al, 2001). Along with evidence that BRCA1 is
important in global nucleotide excision repair (Hartman
and Ford, 2002), these data hint that BRCA1 mutations induce a
genetic profile of which p53 expression and GMP are but
two manifestations, with several factors influencing both
prognosis and response to treatment. However, the role of BRCA1
mutations in the genesis of such a phenotype requires further
investigation.
Angiogenesis is a complex process and its full understanding
will require analysis at the level of morphology and gene
expression. Here, we describe the poor prognosis associated with
GMP, which is a highly characteristic lesion resulting from a gene
expression profile that is as yet undefined. As antiangiogenic
therapy is currently under intense investigation, it will be
important to establish whether the presence of GMP alters the
effectiveness of such therapies.
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Table 2 Cox proportional hazards model for breast cancer specific mortality
Univariate analysis Multivariate analysis (n¼247)
Variable RR (95% CI) P-value RR (95% CI) P-value
Tumour size (cm)
o2 1.0 1.0
X2 2.8 (1.6-4.9) 0.0002 1.6 (0.9-3.0) 0.1
Nuclear grade
a 2.5 (1.7-3.5) 0.0001 1.6 (1.03-2.4) 0.04
ER status
Positive 1.0 1.0
Negative 3.0 (1.8-4.8) 0.0001 1.7 (0.95-3.0) 0.07
Lymph nodes
Negative 1.0 1.0
Positive 2.5 (1.5-4.4) 0.0007 2.3 (1.3-3.4) 0.004
Mutation carrier status
Non-carriers 1.0 1.0
BRCA1 carriers 1.7 (0.9-3.4) 0.1
BRCA2 carriers 1.9 (0.6-6.2) 0.3
BRCA1/BRCA2 carriers 1.8 (0.96-3.2) 0.07




Positive 2.5 (1.5-4.1) 0.0003 1.3 (0.7-2.2) 0.4
GMP
a 2.4 (1.6-3.5) 0.0001 1.9 (1.2-3.0) 0.006
ER¼oestrogen receptor; GMP¼glomeruloid microvascular proliferation; IHC¼immunohistochemistry; MVD¼microvascular density. The model was adjusted for cases with
missing tumour size (n¼13) and missing lymph node status (n¼23)
aAs a continuous variable.
bBRCA1/BRCA2 carriers combined compared with non-carriers.
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